热门资讯> 正文
Sunshine Bizerma获得两种新抗生素在加拿大的营销权
2025-03-24 20:19
- Sunshine Biopharma (NASDAQ:SBFM) Monday said that it has signed a strategic agreement granting it the rights to market two new generic antibiotics in Canada.
- The company anticipates launching these new products through its wholly-owned Canadian subsidiary, Nora Pharma, in the next six to nine months following regulatory approval.
- According to BioSpace, the global antibiotics market size in 2024 was estimated at $53.9 billion and is expected to reach approximately $85.8 billion by 2033, representing a compound annual growth rate of 5.3%.
More on Sunshine Biopharma
- Seeking Alpha’s Quant Rating on Sunshine Biopharma
- Historical earnings data for Sunshine Biopharma
- Financial information for Sunshine Biopharma
推荐文章
国庆节后恒指上涨概率超72%！假期前后如何布局？
华盛早报 | 估值警钟敲响！鲍威尔称美股估值相当高；“木头姐”豪掷2100万美元买入阿里等中概股
美股机会日报 | 凌晨00:35！鲍威尔将发表重要讲话；阿里Qwen团队今晚将发布6个“新东西”
华盛早报 | 美联储理事米兰“首秀”，呼吁激进降息；英伟达涨近4%市值突破4.5万亿美元
美股机会日报 | 华尔街乐观押注：利率降幅将远超美联储预测！以太坊跳水重挫超5%，加密货币概念股BitMine盘前一度跌近10%
一图看懂 | 两只易方达ETF开启认购！入场门槛为1500港元
美联储政策路径不确定性仍存 中期美债备受交易员青睐
特朗普的H-1B签证10万美元新规引发科技公司混乱
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
